Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.2.96 CHF
Change Today -0.02 / -0.67%
Volume 12.4K
ADXN On Other Exchanges
Symbol
Exchange
ADXN is not on other exchanges.
As of 11:43 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

addex pharmaceuticals ltd (ADXN) Snapshot

Open
SFr.3.00
Previous Close
SFr.2.98
Day High
SFr.3.00
Day Low
SFr.2.96
52 Week High
01/13/15 - SFr.4.67
52 Week Low
12/29/14 - SFr.2.22
Market Cap
34.6M
Average Volume 10 Days
29.8K
EPS TTM
SFr.-0.18
Shares Outstanding
11.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADDEX PHARMACEUTICALS LTD (ADXN)

Related News

No related news articles were found.

addex pharmaceuticals ltd (ADXN) Related Businessweek News

No Related Businessweek News Found

addex pharmaceuticals ltd (ADXN) Details

Addex Therapeutics Ltd, together with its subsidiaries, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia; ADX71149 for an undisclosed CNS disorders; ADX71441 for the treatment of Charcot-Marie-Tooth type 1A neuropathy; and ADX71441 for the treatments of addiction. The company focuses on the discovery of oral allosteric modulators of G-protein coupled receptors. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and collaboration with Dystonia Medical Research Foundation to prepare a phase IIa proof of concept clinical study in a form of dystonia. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

5 Employees
Last Reported Date: 04/30/15
Founded in 2002

addex pharmaceuticals ltd (ADXN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.384.0K
Compensation as of Fiscal Year 2014.

addex pharmaceuticals ltd (ADXN) Key Developments

Addex Therapeutics Ltd. Announces Board Appointments

Addex Therapeutics Ltd. announced at its 2015 annual general meeting, the company elected Raymond Hill  as member  of the  board of directors and  member of the compensation  committee and  elected  Tim  Dyer  as  member  of  the  board of  directors.

Addex Therapeutics Ltd. Proposes Amendments to the Articles of Association

Addex Therapeutics Ltd. announced that it will propose amendments to the articles of association at the annual general meeting to be held on June 11, 2015.

Addex Therapeutics Ltd., Annual General Meeting, Jun 11, 2015

Addex Therapeutics Ltd., Annual General Meeting, Jun 11, 2015., at 11:00 Central European Standard Time. Location: 3rd floor of 17. Agenda: To approve the annual report, the annual financial statements and the consolidated financial statements for the business year 2014; to consider consultative vote on the compensation report for the business year 2014; to consider the appropriation of the results; to consider discharge of the members of the board of directors and of the executive management; to consider elections of members of the board of directors and re-election of the chairman of the board of directors; to consider the elections of Vincent Lawton and Raymond hill as the members of the compensation committee; to consider the re-election of PricewaterhouseCoopers SA, Geneva as auditors; to consider the re-election; to consider the amendments to the articles of association; to approve the compensation of the members of the board of directors and of the executive management; and to consider other proposals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXN:SW SFr.2.96 CHF -0.02

ADXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADXN.
View Industry Companies
 

Industry Analysis

ADXN

Industry Average

Valuation ADXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADDEX PHARMACEUTICALS LTD, please visit www.addextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.